Table 1.
Demographic and clinical characteristics at baseline of the overall population and prior treatment subgroups.
Fig 1.
ARR in the overall population and prior treatment subgroups.
Abbreviatures: BRACE: Betaseron (interferon beta-1b sc), Rebif (interferon beta-1a sc), Avonex (interferon beta-1a im), Copaxone (Glatiramer acetate), and Extavia (interferon beta-1b sc); EDSS, Expanded Disability Status Scale; IQR, interquartile range; N: Number of patients with available data for relapses; NTZ, natalizumab.
Fig 2.
Expanded Disability Status Scale evolution in the overall population and prior treatment subgroups.
Abbreviatures: BRACE: Betaseron (interferon beta-1b sc), Rebif (interferon beta-1a sc), Avonex (interferon beta-1a im), Copaxone (Glatiramer acetate), and Extavia (interferon beta-1b sc); EDSS, Expanded Disability Status Scale; IQR, interquartile range; N: Number of patients with available data for EDSS at that visit; NTZ, natalizumab. *Significant (p<0.05) paired comparation EDSS at month 6, year 1, year 2, year 3, and year 4 vs year prior to fingolimod and vs baseline are shown. Comparisons have been conducted considering the patients with EDSS data at both visits. Not significant comparisons are not marked.
Fig 3.
Patients free from T1 Gd+ Lesions in the overall population and prior treatment subgroups.
Abbreviatures: BRACE: Betaseron (interferon beta-1b sc), Rebif (interferon beta-1a sc), Avonex (interferon beta-1a im), Copaxone (Glatiramer acetate), and Extavia (interferon beta-1b sc); EDSS, Expanded Disability Status Scale; IQR, interquartile range; N: Number of patients with available data for T1 Gd+ Lesions; NTZ, natalizumab.
Fig 4.
Patients free from new/enlarged T2 lesions in the overall population and prior treatment subgroups.
Abbreviatures: BRACE: Betaseron (interferon beta-1b sc), Rebif (interferon beta-1a sc), Avonex (interferon beta-1a im), Copaxone (Glatiramer acetate), and Extavia (interferon beta-1b sc); EDSS, Expanded Disability Status Scale; IQR, interquartile range; N: Number of patients with available data for T2 Lesions; NTZ, natalizumab.
Fig 5.
MS activity after 4 years vs prior year of fingolimod treatment in the overall population and prior treatment subgroups.
Abbreviatures: BRACE: Betaseron (interferon beta-1b sc), Rebif (interferon beta-1a sc), Avonex (interferon beta-1a im), Copaxone (Glatiramer acetate), and Extavia (interferon beta-1b sc); EDSS, Expanded Disability Status Scale; IQR, interquartile range; N: Number of patients with available data for radiological (A), clinical (B), or radiological and clinical (C) activity; NTZ, natalizumab.
Table 2.
Patients with concomitant medication after fingolimod initiation.
Table 3.
Adverse events for the overall population (reported in ≥1% of patients).